Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
708 (USA) · Dr. Kim
consented 2012-12-07
Adverse events
Mild APPLICATION SITE ERYTHEMA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-04-10 (study day 125.0); relationship: PROBABLE
Mild APPLICATION SITE ERYTHEMA — outcome: RECOVERED/RESOLVED; onset 2013-04-10 (study day 125.0); relationship: PROBABLE
Mild APPLICATION SITE PRURITUS — outcome: RECOVERED/RESOLVED; onset 2013-01-12 (study day 37.0); relationship: PROBABLE
Mild APPLICATION SITE PRURITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-04-10 (study day 125.0); relationship: PROBABLE
Mild APPLICATION SITE PRURITUS — outcome: RECOVERED/RESOLVED; onset 2013-04-10 (study day 125.0); relationship: PROBABLE
Mild DIZZINESS — outcome: RECOVERED/RESOLVED; onset 2012-12-18 (study day 12.0); relationship: POSSIBLE
Mild DIZZINESS — outcome: RECOVERED/RESOLVED; onset 2013-02-02 (study day 58.0); relationship: POSSIBLE
Data queries
No data queries.